ED
56
-3
IFF
60
-2
SLG
53
-13
PX
48
-2
PNC
53
-4
VRSK
61
-5
TDC
39
-3
ADSK
57
-4
WMB
55
-4
CHK
5
-17
CRM
45
-4
HOG
35
-4
M
5
-3
FIS
46
-4
LRCX
42
-4
PCG
78
-7
EFX
69
-5
HAS
38
-13
EXR
59
13
AVB
67
-3
ED
56
-3
IFF
60
-2
SLG
53
-13
PX
48
-2
PNC
53
-4
VRSK
61
-5
TDC
39
-3
ADSK
57
-4
WMB
55
-4
CHK
5
-17
CRM
45
-4
HOG
35
-4
M
5
-3
FIS
46
-4
LRCX
42
-4
PCG
78
-7
EFX
69
-5
HAS
38
-13
EXR
59
13
AVB
67
-3
Financhill
Back

Cartesian Therapeutics 10K Form

Sell
25

RNAC
Cartesian Therapeutics

Last Price:
12.91
Seasonality Move:
-10.23%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RNAC News And Ratings

See the #1 stock for the next 7 days that we like better than RNAC

RNAC Financial Statistics

Sales & Book Value

Annual Sales: $26M
Cash Flow: $-16.03M
Price / Cash Flow: 0
Annual Sales: $-5.69
Price / Book: 0

Profitability

EPS (TTM): -53.46000
Net Income (TTM): $-229.65M
Gross Margin: --
Return on Equity: 0%
Return on Assets: -93.85%

Cartesian Therapeutics Earnings Forecast

Key Cartesian Therapeutics Financial Ratios

  • The Research & Development expenses have been 276.26% of Revenue.
  • The Interest Expense is -1.29% of Operating Income.
  • The Net Earning history of RNAC is -844.91% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 6 years.

Cartesian Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RNAC
Website: cartesiantherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.78
Quick Ratio: 4.7

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RNAC Technical Analysis vs Fundamental Analysis

Sell
25
Cartesian Therapeutics (RNAC) is a Sell

Is Cartesian Therapeutics a Buy or a Sell?